DDInter948 DDInter1833
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Tolvaptan {u} (Compound) resembles {v} (Compound) Conivaptan
Tolvaptan {u} (Compound) binds {v} (Gene) AVPR1A
Tolvaptan {u} (Compound) causes {v} (Side Effect) Renal impairment
Tolvaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Tolvaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Tolvaptan {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Tolvaptan {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Tolvaptan (Compound) resembles Conivaptan (Compound)
Tolvaptan (Compound) binds AVPR1A (Gene)
Tolvaptan (Compound) causes Renal impairment (Side Effect)
Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Tolvaptan may lead to a major life threatening interaction when taken with Leflunomide
Tolvaptan may lead to a major life threatening interaction when taken with Lumacaftor